PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...
PulseSight Therapeutics completes patient enrolment in phase I trial of PST-611 to treat dry AMD/geographic atrophy: Paris, France Friday, January 23, 2026, 18:00 Hrs [IST] PulseS ...
Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...
Age-related macular degeneration (AMD) once meant a slow, irreversible loss of vision, and many people still believe that's true. But the AMD of today isn't the AMD of ...
An early study testing the effects of a stem cell implant has found that the device is safe and helped some patients see better ...
The evidence evaluating the effect of cataract surgery on the chances people with dry age-related macular degeneration (AMD) will convert to the more severe wet form of the condition has been uneven ...
The MarketWatch News Department was not involved in the creation of this content. Partnership includes manufacturing and launch in Australia and New Zealand, with additional markets to follow. WINDSOR ...
At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...
Hosted on MSN
What is age-related macular degeneration – as Dame Judi Dench opens up about her deteriorating eyesight
Ahead of her 91st birthday on Tuesday, Dame Judi Dench has opened up about her worsening eyesight. The beloved actress was first diagnosed with age-related macular degeneration (AMD) in 2012, and ...
Annexon, Inc. reports complete enrollment in the ARCHER II trial for vonaprument, targeting dry AMD with topline data due 2026. Annexon, Inc. announced the successful completion of enrollment for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results